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Recent evidence has suggested that allogeneic engraftment failure
of puriﬁed hematopoietic stem cells (HSC) can be decreased by
including a BM-derived CD8/TCR- facilitating cell (FC) or
CD8

/TCR T cell populations. Therefore, the present study
investigated the clinically important question of GVHD effector
activity of these donor CD8 populations in the setting of HSC
transplantation. METHODS: A puriﬁed cell component-based
model of lethal GVHD was established using a P3 F1
(B63 B6D2F1) murine model. All recipients were lethally irradi-
ated and reconstituted with as few as 2000 puriﬁed HSC (Sca
ckit Lin-) of donor alone or together with one of the following
lymphoid subsets: 1) TCR splenic T cells; 2) CD8/TCR
BM-derived T cells (TBM) and 3) the CD8/TCR- FC popu-
lation. RESULTS: As expected, all recipients of puriﬁed HSC
exhibited little evidence of GVHD with clinical scores of 1.60.3,
on a ﬁve parameter clinical scale ranging from 0 to 10. Addition of
puriﬁed TCR splenocytes in the donor inoculum, as a positive
effector control, resulted in lethal GVHD with a 50% mortality
and a clinical score of 4.30.9. Similarly, recipients of HSC plus
BM-derived CD8 T cells rapidly exhibited lethal GVHD with
decreased survival and signiﬁcant morbidity (4.30.7). In marked
contrast, no clinical evidence of GVHD was present in recipients
of HSCFC (1.550.1). Histological analysis of the gut demon-
strated minimal to no evidence of GVHD in 85% of these recip-
ients whereas 57% of HSCTBM demonstrated moderate to se-
vere GVHD. CONCLUSION: These ﬁndings suggest that in
contrast to CD8 TBM, the FC, which expresses a unique FCp33-
TCR heterodimer in place of TCR, does not result in signif-
icant GVHD even in an aggressive P3 F1 model. Therefore,
supplementation of the donor inoculum with the FC has the
potential to offer a safer, more efﬁcient approach to enhance
alloengraftment in the absence of GVHD.
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RAPID CONVERSION TO FULL CHIMERISM AFTER REDUCED INTENSITY
CONDITIONING (RIC) AND TRANSPLANTATION OF T-CELL DEPLETED
LARGE NUMBERS OF CD34 STEM AND CD56 NATURAL KILLER
(NK) CELLS OBTAINED FROM MOBILIZED HAPLOIDENTICAL DONORS
Benaim, E., Hale, G., Horwitz, E., Leung, W., Woodard, P., Yusuf, U.,
Handgretinger, R. St Jude Children’s Research Hospital, Memphis, TN.
Since alloreactive NK cells have recently been described to exert
an anti-leukemic effect, to reduce GvHD and to facilitate engraft-
ment across HLA-barriers, we have designed a protocol to pro-
mote rapid engraftment of haploidentical stem cells after Reduced
Intensity Conditioning (RIC) in patients with refractory hemato-
logical malignancies. Haploidentical donors (if available, NK-allo-
reactive donors were preferentially chosen and 5 out of 8 donors
had a constellation of NK-alloreactivity) were mobilized using
G-CSF and/or GGM-CSF. In order to cotransplant large num-
bers of CD56 NK cells together with stem cells, PBSCs were
negatively depleted of T-lymphocytes using an anti-CD3 mono-
clonal antibody conjugated to magnetic microbeads and high gra-
dient magnetic cell sorting utilizing the automated CliniMACS
device (Miltenyi Biotec).The RIC regimen included Fludarabine
(200 mg/m2), Thiotepa (10 mg/m2) and Melphalan (60 to 140
mg/m2). Rituximab (375 mg/m2) was given prior to the stem cell
infusion. Immunosuppressive regimen included Muromonab-CD3
(OKT3) and Cyclosporine or Mycophenolate mofetil. We trans-
planted 8 patients (5 AML-relapse, 1 therapy-related secondary
MDS, 1 Biphenotypic leukemia-CR2, 1 CML-blastic crisis). 5
patients have received a previous allogeneic HSCT. The mean
total MNC, CD34 and CD3 cell counts per kg infused were
8.16 x 108 (2.6 -15 x 108), 15.13 x106 (2.14-37.54 x 106) and 0.243
x 106 (0.01-0.476 x 106) respectively. The number of infused
CD56 NK cells ranged from 44 to 200 x 106/kg. All patients
achieve early 100% peripheral blood donor chimerisms with a
median of 14.5 (8-20) days. 7 patients achieve primary engraftment
(ANC  500) at a mean of 11.14 (7-14) days. One patient had only
early lymphoid engraftment. He was successfully engrafted by day
45 after repeated plasmapheresis and a stem cell boost. No early
transplant-related mortality was seen. 3 patients had transient
grade 1-2 skin GVHD that was controlled with immunosuppres-
sion and 1 patient developed liver GvHD. 5 of the 8 patients are
alive with short follow-up. Overall, patients tolerated the RIC well
and achieved very rapid chimeric engraftment. Haploidentical
transplantation of T-cell depleted PBSC after RIC might be a
therapeutic option for patients with advanced malignant diseases
and a platform for further exploiting the role of alloreactive NK
cells in the reduction of GvHD and the facilitation of engraftment
in patients with nonmalignant diseases.
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ALLOGENEIC STEM-CELL TRANSPLANTATION WITH MATCHED UNRE-
LATED DONORS IN ELDERLY PATIENTS (55-67 YEARS); AGE BY ITSELF
IS NO LONGER A CONTRAINDICATION
Shimoni, A.1, Kroger, N.2, Zander, A.R.2, Yeshurun, M.1, Hardan, I.1,
Nagler, A.1 1. Chaim Sheba Medical Center, Tel-Hashomer, Israel; 2.
University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Allogeneic stem-cell transplantation (SCT) is a potentially cura-
tive approach for patients (pts) with hematologic malignancies.
The introduction of low-intensity conditioning (LIC) regimens
reduced SCT-related toxicity and allowed treatment of elderly pts.
However, there is only limited data on the feasibility of this
approach in SCT using unrelated donors, in elderly pts over age 55
years. Thirty-ﬁve pts were included in this study. The median age
was 58 years (range, 55-67). Eleven pts were age 60 and above at
the time of SCT. Diagnoses included myeloid malignancies (n 
22); AML (n  13, 8 secondary), MDS (n  4), CML (n  3),
myeloﬁbrosis (n  2), and lymphoid malignancies (n  13); mul-
tiple myeloma (n  9) and non-Hodgkin’s lymphoma (n  4).
Conditioning regimens included ﬂudarabine (F) and busulfan (FB,
n 16), F and melphalan (FM, n 12), F and treosulfan (FT, n
5), and F and low-dose TBI (n  2). All pts were also given ATG
during conditioning. With a median follow-up of one year, 18 pts
are alive and 16 are disease-free. The 1-year OS and DFS are 46
10%, and 3311%, respectively. Five pts died of disease progres-
sion, and 12 of treatment-related causes (TRM), including acute
GVHD (n 2), infection (n 2), liver toxicity (n 3), pulmonary
toxicity (n  2), TTP (n  2), and heart failure (n  1). The
estimated risk for TRM was 379%. A limited multivariant anal-
ysis identiﬁed conditioning with FM (rather than FB or FT), and
diagnosis of lymphoid malignancy as risk factors for TRM with
hazard ratios of 21.6 (p  0.02) and 11.2 (p  0.05), respectively.
Age category was not predictive of TRM; only 2 of the 11 pts over
age 60 had TRM. Pt or donor gender and disease status at SCT
were also not signiﬁcant risk factors. Pt number and follow-up
duration are too small to assess risk factors for OS and DFS. When
only the 20 pts with myeloid malignancies conditioned with FB or
FT were analyzed, the estimated TRM, OS and DFS rates were
2811%, 6012% and 6012%, respectively. In conclusion,
SCT from unrelated donors is feasible in selected groups of elderly
patients when using LIC regimens. Toxicity is acceptable and not
signiﬁcantly different from that observed in younger patients. Fa-
vorable outcome was observed in myeloid malignancies. Age by
itself should not rule out SCT from unrelated donors.
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A COMBINATIONAL METHOD TO IDENTIFY HLA-DRB1*0401 INDIVID-
UALS FOR IMMUNOTHERAPEUTIC STUDIES
Huang, X.1, Gebe, J.A.2, Blazar, B.1, Zhou, X.1 1. University of
Minnesota Cancer Center, Department of Pediatrics, Division of Blood
and Marrow Transplantation, Minneapolis, MN; 2. Benaroya Research
Institute at Virginia Mason, Seattle, WA.
HLA-DR4 is present at high frequencies in many populations and
presents many well-characterized peptide antigens to T cells in dis-
eases including infection, autoimmune disorders, transplant rejection
and cancer. We have established a combinational, simple and eco-
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